Digital Transformation in Drug Regulatory Affairs: Implications for Supply Chain Governance and Market Access

Abstract

The pharmaceutical industry is undergoing an unprecedented digital transformation, reshaping the architecture of drug regulatory affairs and its intersection with supply chain governance and market access strategies. Regulatory authorities worldwide, including the US Food and Drug Administration (USFDA), European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO), are progressively adopting digital platforms, electronic submission systems, and data-driven compliance frameworks. This study examines how digital transformation in regulatory affairs influences supply chain governance efficiency and market access outcomes across pharmaceutical firms operating in emerging and developed economies. A mixed-methods research design was employed, drawing on primary survey data from 60 pharmaceutical companies across India, Southeast Asia, and the European Union, supplemented by secondary analysis of regulatory framework documents and digital adoption indices. Findings reveal that firms with high digital regulatory maturity achieved a 28.6% reduction in time-to-market for new drug approvals, a 34.2% improvement in supply chain compliance audit scores, and a 22.1% reduction in regulatory non-conformance incidents. Electronic Common Technical Document (eCTD) adoption, real-time pharmacovigilance platforms, and AI-assisted regulatory intelligence tools emerged as the three most impactful digital interventions. The study concludes that digital transformation in regulatory affairs is no longer a competitive differentiator but a governance imperative, with direct implications for supply chain resilience, market access speed, and organizational compliance culture.